Rosiglitazone and Insulin in T1DM Adolescents

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Type 1 Diabetes is the most common life-long disorder with onset in childhood. Patients need insulin injections, blood sugar monitoring several times each day, and adhere to a strict diet. Adequate control of blood glucose is essential to prevent long term kidney and eye complications that result in kidney failure and blindness. Adolescence is a time when diabetes is difficult to control, due in part to high growth hormone levels causing insulin resistance ( a state where the body does not respond as strongly to insulin). This study will test whether treatment with rosiglitazone (an oral medication used frequently in type 2 diabetes) will reduce the insulin resistance of adolescence and improve the control of type 1 diabetes during puberty.

• Phase: Phase 4

Details

• Lead Sponsor: The University of New South Wales
• Collaborators: National Health and Medical Research Council, Australia; Novo Nordisk A/S; Sydney Children's Hospitals Network; Sydney Children's Network
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• T1DM duration > 1year

• age 10-18years

• HbA1c > 8%

• puberty > Tanner stage 2 breast or testis >4ml

Exclusion Criteria:

• known non-compliance

• hypo unaware